1. The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer
- Author
-
Eugene Tulchinsky, Tamer Yagci, Seval Kilic, Maria Antonette Lopez, Rahul Sreekumar, Brendan D. Price, Metin Çetin, Muhammad Emaduddin, Ashish Patel, Sule Erdemir, Karwan A. Moutasim, Hajir Al-Saihati, Marta Salgado Navio, A. Emre Sayan, John N. Primrose, Geert Berx, Nathan Curtis, Gareth J. Thomas, Massimiliano Mellone, and Alex H. Mirnezami
- Subjects
0301 basic medicine ,Cancer Research ,DNA Repair ,Organoplatinum Compounds ,Transcription, Genetic ,Colorectal cancer ,TO-MESENCHYMAL TRANSITION ,Leucovorin ,Mice ,0302 clinical medicine ,FOLFOX ,Antineoplastic Combined Chemotherapy Protocols ,Medicine and Health Sciences ,ZEB1 ,RC254-282 ,Research Articles ,ZEB2 ,CHEMORESISTANCE ,MOLECULAR-MECHANISMS ,Liver Neoplasms ,EMT ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,General Medicine ,CHEMOTHERAPY ,DNA-Binding Proteins ,Oncology ,030220 oncology & carcinogenesis ,DNA-REPAIR ,Molecular Medicine ,Biomarker (medicine) ,Fluorouracil ,Colorectal Neoplasms ,medicine.drug ,Research Article ,EXPRESSION ,Epithelial-Mesenchymal Transition ,PROTEINS ,DNA repair ,03 medical and health sciences ,Cell Line, Tumor ,Genetics ,medicine ,Animals ,Humans ,Epithelial–mesenchymal transition ,neoplasms ,Zinc Finger E-box Binding Homeobox 2 ,business.industry ,oxaliplatin ,Biology and Life Sciences ,BLADDER ,medicine.disease ,Endonucleases ,Xenograft Model Antitumor Assays ,digestive system diseases ,Oxaliplatin ,030104 developmental biology ,Drug Resistance, Neoplasm ,CELLS ,Cancer research ,ERCC1 ,business ,ERCC4 ,Nucleotide excision repair - Abstract
Resistance to adjuvant chemotherapy is a major clinical problem in the treatment of colorectal cancer (CRC). The aim of this study was to elucidate the role of an epithelial to mesenchymal transition (EMT)‐inducing protein, ZEB2, in chemoresistance of CRC, and to uncover the underlying mechanism. We performed IHC for ZEB2 and association analyses with clinical outcomes on primary CRC and matched CRC liver metastases in compliance with observational biomarker study guidelines. ZEB2 expression in primary tumours was an independent prognostic marker of reduced overall survival and disease‐free survival in patients who received adjuvant FOLFOX chemotherapy. ZEB2 expression was retained in 96% of liver metastases. The ZEB2‐dependent EMT transcriptional programme activated nucleotide excision repair (NER) pathway largely via upregulation of the ERCC1 gene and other components in NER pathway, leading to enhanced viability of CRC cells upon oxaliplatin treatment. ERCC1‐overexpressing CRC cells did not respond to oxaliplatin in vivo, as assessed using a murine orthotopic model in a randomised and blinded preclinical study. Our findings show that ZEB2 is a biomarker of tumour response to chemotherapy and risk of recurrence in CRC patients. We propose that the ZEB2‐ERCC1 axis is a key determinant of chemoresistance in CRC., Here, we show that the expression of ZEB2 marks reduced overall and disease‐free survival in primary and secondary colorectal cancers (CRCs). ZEB2 overexpression promoted chemoresistance to oxaliplatin in vitro and in vivo by transcriptionally activating nucleotide excision repair genes ERCC1 and ERCC4. Overall ZEB2 is a promising biomarker predicting both therapy response and metastatic ability of CRCs.
- Published
- 2021